We would love to hear your thoughts about our site and services, please take our survey here.
A fool always see Red when the flags are Green!
Project Veritas uses deceptive techniques, including recording people without their knowledge and misrepresenting their employees' identities and purposes. It hires former U.S. and British military and intelligence agents to train its employees, who are often referred to as "agents" or "operatives" in internal documents. Internal memos show that Project Veritas clears these activities with its legal team to stay within the boundaries of the law, which The New York Times says is a sign of Project Veritas' interest in "using tactics that test the boundaries of legality and are outside of mainstream reporting techniques."Rolling Stone called Project Veritas' reporting practices "dubious" with their reporters actively manipulating their targets into the reactions.
Hvo market capitalisation is £116 million.
Cashintime, I think you meant to type 2023.
Is there a Chariot Telegram group anyone know?
Stt1, your comment "A lot of talk, a lot of jam tomorrow." I expect you must have noticed we are already get plenty of Jam as can be seen by Polb. Your comment "Actions speak louder than words." As you are aware , revenue is growing also cash is growing and we have a new facility to produce more jam. Orph is in fact a rare AIM company which is not promising jam tomorrow but is in fact producing jam as you write your comment. Just keep your mouth open for your share of jam.
Thank you Wallyj for your informative summary.
Or is it?
Could be A 544,000 BUY@ 19.50p
?
A 544,000 sell @ 19.50p?
Last year's interim results was 30/09/20, this year's interim on the 20th, ten days earlier which would indicate good interim results.
Courtesy of Cottoner on Advfn:
Highlighted in the Times Market Report
Drug tester’s £8m contract win
Open Orphan shares rose after the Aim company bagged a new contract worth £8.1 million with one of Europe’s biggest drugmakers.
Hvivo, one of Open Orphan’s subsidiaries, will test an asthma drug now in development. The company said the drug is owned by a “top five European pharmaceutical company” and industry insiders suggested it was GlaxoSmithKline.
Hvivo will recruit people with asthma and infect them with the common cold, which exacerbates their symptoms. The researchers will then administer the treatment and monitor its effects.
The hundred or so people taking part will be paid about £3,500 for two weeks of their time. The trial is to begin in the first half of next year.
Earlier this year Hvivo was hired to infect people with coronavirus to test vaccines against the various strains.
Cathal Friel, Open Orphan’s executive chairman, said that there has been an “enormous expansion of investment” in the respiratory treatment market and that his company was “ideally situated” to take advantage of the boom.
News of the contract win sent the stock 3½p, or 17.6 per cent, up to 24½p.
I am not interested in the next few months, but the next few years. CF is a great entrepreneur who has a vision for Orph and is looking for a great return on his investment. Like CF, I am, as an investor in Orph and therefore part owner in a business which is not only profitable and generating great cash flow but also in the process of creating new spin off companies to enhance shareholders value. Yes, I will not sell my shares for many years or until CF departs.
Could be new employees buying shares in the market. Employees knows how good Orph are performing.
25 Feb '21 - 07:35 - 12762
For the record, in today's new Shares Magazine there's a special Growth and Innovation supplement focusing on four companies, one of which is ORPH. It concludes:
"SIGNIFICANT NEW GROWTH OPPORTUNITIES
Open Orphan has been developing its Disease in Motion® platform which includes the world’s largest database of infectious disease progression data which can power wearables. The digital platform is now patented with applications for big tech and wearables; pharma and biotech companies.
The Company is also actively working towards the monetisation of its non-core assets: Imutex, Prep Biopharm and Immune modulator.
Since its formation, Open Orphan has consistently delivered on its objectives and was recently listed as a top 10 European CRO (contract research organisation).
The delivery of pipeline from a broad customer base and winning of major contracts including the Covid-19 Human Challenge Programme has resulted in the group reaching profitability in 2020. With global healthcare investment increasing, Open Orphan is in a strong position to deliver value for its shareholders and continues in the months and years ahead to be one of the fastest growing stocks on the London and Dublin exchanges."
Thank you Golsachs, for the link, very informative insight on SPACS.
Conservbio is the new name of Seek.
In layman's terms; small companies comes up with revolutionary new ideas ( Amazon) which is embraced by the market because of the benefits it provides and these small companies becomes Giant companies. Simple idea but hard to implement, but we all know that TILS will not only be able to implement but also become a giant in its field of expertise.
Thank you Wallyj for taking the time to update myself and the rest of ORPH investors who were unable to watch the presentation. We are very privileged to have such dedicated investor like yourself keeping us updated.